Exelixis Valuation

EXEL Stock  USD 36.46  0.53  1.48%   
At this time, the firm appears to be overvalued. Exelixis shows a prevailing Real Value of $32.73 per share. The current price of the firm is $36.46. Our model computes the value of Exelixis from reviewing the firm fundamentals such as Shares Outstanding of 285.58 M, current valuation of 9.27 B, and Profit Margin of 0.22 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Exelixis' valuation include:
Price Book
4.5094
Enterprise Value
9.3 B
Enterprise Value Ebitda
14.5702
Price Sales
5.002
Forward PE
24.0964
Overvalued
Today
36.46
Please note that Exelixis' price fluctuation is very steady at this time. Calculation of the real value of Exelixis is based on 3 months time horizon. Increasing Exelixis' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Exelixis stock is determined by what a typical buyer is willing to pay for full or partial control of Exelixis. Since Exelixis is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Exelixis Stock. However, Exelixis' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  36.46 Real  32.73 Target  25.76 Hype  36.51 Naive  36.21
The intrinsic value of Exelixis' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Exelixis' stock price.
32.73
Real Value
40.11
Upside
Estimating the potential upside or downside of Exelixis helps investors to forecast how Exelixis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Exelixis more accurately as focusing exclusively on Exelixis' fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
0.430.490.56
Details
Hype
Prediction
LowEstimatedHigh
34.1136.5138.91
Details
Naive
Forecast
LowNext ValueHigh
33.8136.2138.61
Details
22 Analysts
Consensus
LowTarget PriceHigh
23.4425.7628.59
Details
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Exelixis' intrinsic value based on its ongoing forecasts of Exelixis' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Exelixis' closest peers.

Exelixis Cash

190.93 Million

Exelixis Valuation Trend

Knowing Exelixis' actual value is paramount for traders when making sound investment determinations. Using both Exelixis' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.

Exelixis Revenue by Product

Exelixis Total Value Analysis

Exelixis is currently forecasted to have valuation of 9.27 B with market capitalization of 10.41 B, debt of 189.94 M, and cash on hands of 1.53 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Exelixis fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
9.27 B
10.41 B
189.94 M
1.53 B

Exelixis Investor Information

About 89.0% of the company shares are held by institutions such as insurance companies. The book value of Exelixis was currently reported as 7.96. The company has Price/Earnings To Growth (PEG) ratio of 2.61. Exelixis had not issued any dividends in recent years. Based on the key indicators related to Exelixis' liquidity, profitability, solvency, and operating efficiency, Exelixis is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in December.

Exelixis Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Exelixis has an asset utilization ratio of 62.2 percent. This suggests that the Company is making $0.62 for each dollar of assets. An increasing asset utilization means that Exelixis is more efficient with each dollar of assets it utilizes for everyday operations.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Exelixis Ownership Allocation

Exelixis holds a total of 285.58 Million outstanding shares. The majority of Exelixis outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Exelixis to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Exelixis. Please pay attention to any change in the institutional holdings of Exelixis as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Exelixis Profitability Analysis

The company reported the previous year's revenue of 1.83 B. Net Income was 207.76 M with profit before overhead, payroll, taxes, and interest of 1.55 B.

About Exelixis Valuation

We use absolute and relative valuation methodologies to arrive at the intrinsic value of Exelixis. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Exelixis based exclusively on its fundamental and basic technical indicators. By analyzing Exelixis's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Exelixis's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Exelixis. We calculate exposure to Exelixis's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Exelixis's related companies.
Last ReportedProjected for Next Year
Gross Profit1.8 B1.8 B
Pretax Profit Margin 0.20  0.22 
Operating Profit Margin 0.20  0.21 
Net Profit Margin 0.16  0.17 
Gross Profit Margin 0.96  1.14 

Exelixis Growth Indicators

Investing in growth stocks can be very risky. If the company such as Exelixis does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding321.5 M
Quarterly Earnings Growth Y O Y121.699
Forward Price Earnings24.0964

Exelixis Current Valuation Indicators

Exelixis' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Exelixis' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Exelixis, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Exelixis' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Exelixis' worth.
When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
121.699
Earnings Share
1.55
Revenue Per Share
7.032
Quarterly Revenue Growth
0.143
Return On Assets
0.1281
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.